Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity

Nature Medicine

Volumn 13, Issue 3, 2007, Pages 324-331

  Trivedi, Chinmay M ^a   Luo, Yang ^a,f   Yin, Zhan ^a,g   Zhang, Maozhen ^a,h   Zhu, Wenting ^a   Wang, Tao ^a   Floss, Thomas ^b   Goettlicher, Martin ^c   Noppinger, Patricia Ruiz ^d   Wurst, Wolfgang ^b   Ferrari, Victor A ^a   Abrams, Charles S ^a   Gruber, Peter J ^a,e   Epstein, Jonathan A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^g INSTITUTE OF HYDROBIOLOGY   (China)

^h SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 6 BROMOINDIRUBIN 3' OXIME; 6 BROMOINDIRUBIN 3' OXIME; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; ISOPRENALINE; PROTEIN KINASE; PROTEIN KINASE B; TRICHOSTATIN A; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENE INACTIVATION; HEART; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; THYMOMA;

ANIMALS; CARDIOMEGALY; ENZYME ACTIVATION; FETUS; GLYCOGEN SYNTHASE KINASE 3; HISTONE DEACETYLASES; ISOENZYMES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

EID: 33847695362     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1552     Document Type: Article

References (41)

1. Jessup, M. & Brozena, S. Heart failure. N. Engl. J. Med. 348, 2007-2018 (2003).
2. Schrier, R.W. & Abraham, W.T. Hormones and hemodynamics in heart failure. N. Engl. J. Med. 341, 577-585 (1999).
3. Huss, J.M. & Kelly, D.P. Mitochondrial energy metabolism in heart failure: a question of balance. J. Clin. Invest. 115, 547-555 (2005).
4. Hoshijima, M. & Chien, K.R. Mixed signals in heart failure: cancer rules. J. Clin. Invest. 109, 849-855 (2002).
5. Heineke, J. & Molkentin, J.D. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat. Rev. Mol. Cell Biol. 7, 589-600 (2006).
6. Izumo, S., Nadal-Ginard, B. & Mahdavi, V. Protooncogene induction and reprogramming of cardiac gene expression produced by pressure overload. Proc. Natl. Acad. Sci. USA 85, 339-343 (1988).
7. Wolffe, A.P. Histone deacetylase: a regulator of transcription. Science 272, 371-372 (1996).
8. Ekwall, K. Genome-wide analysis of HDAC function. Trends Genet. 21, 608-615 (2005).
9. Thiagalingam, S. et al. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann. NY Acad. Sci. 983, 84-100 (2003).
10. McKinsey, T.A. & Olson, E.N. Cardiac histone acetylation-therapeutic opportunities abound. Trends Genet. 20, 206-213 (2004).
11. Zhang, C.L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479-488 (2002).
12. McKinsey, T.A. & Olson, E.N. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J. Clin. Invest. 115, 538-546 (2005).
13. Chang, S. et al. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol. 24, 8467-8476 (2004).
14. Antos, C.L. et al. Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J. Biol. Chem. 278, 28930-28937 (2003).
15. Kook, H. et al. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J. Clin. Invest. 112, 863-871 (2003).
16. Kee, H.J. et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 113, 51-59 (2006).
17. Kong, Y. et al. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113, 2579-2588 (2006).
18. Kook, H. & Epstein, J.A. Hopping to the beat. Hop regulation of cardiac gene expression. Trends Cardiovasc. Med. 13, 261-264 (2003).
19. Chen, F. et al. Hop is an unusual homeobox gene that modulates cardiac development. Cell 110, 713-723 (2002).
20. Shin, C.H. et al. Modulation of cardiac growth and development by HOP, an unusual homeodomain protein. Cell 110, 725-735 (2002).
21. Chen, C.S., Weng, S.C., Tseng, P.H., Lin, H.P. & Chen, C.S. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 280, 38879-38887 (2005).
22. Yuan, Z.L., Guan, Y.J., Chatterjee, D. & Chin, Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307, 269-273 (2005).
23. Choi, J.D. et al. A novel variant of Inpp5f is imprinted in brain, and its expression is correlated with differential methylation of an internal CpG island. Mol. Cell. Biol. 25, 5514-5522 (2005).
24. Minagawa, T., Ijuin, T., Mochizuki, Y. & Takenawa, T. Identification and characterization of a sac domain-containing phosphoinositide 5-phosphatase. J. Biol. Chem. 276, 22011-22015 (2001).
25. Dorn, G.W. II & Force, T. Protein kinase cascades in the regulation of cardiac hypertrophy. J. Clin. Invest. 115, 527-537 (2005).
26. Haq, S. et al. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J. Cell Biol. 151, 117-130 (2000).
27. Antos, C.L. et al. Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc. Natl. Acad. Sci. USA 99, 907-912 (2002).
28. Morisco, C. et al. The Akt-glycogen synthase kinase 3beta pathway regulates transcription of atrial natriuretic factor induced by beta-adrenergic receptor stimulation in cardiac myocytes. J. Biol. Chem. 275, 14466-14475 (2000).
29. Hardt, S.E. & Sadoshima, J. Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ. Res. 90, 1055-1063 (2002).
30. Zhang, F., Phiel, C.J., Spece, L., Gurvich, N. & Klein, P.S. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J. Biol. Chem. 278, 33067-33077 (2003).
31. Bolden, J.E., Peart, M.J. & Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug. Discov. 9, 769-784 (2006).
32. Marks, P.A., Richon, V.M., Breslow, R. & Rifkind, R.A. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13, 477-483 (2001).
33. Baldinu, P. et al. Identification of a novel candidate gene, CASC2, in a region of common allelic loss at chromosome 10q26 in human endometrial cancer. Hum. Mutat. 23, 318-326 (2004).
34. Peiffer-Schneider, S. et al. Mapping an endometrial cancer tumor suppressor gene at 10q25 and development of a bacterial clone contig for the consensus deletion interval. Genomics 52, 9-16 (1998).
35. Marks, P.A. & Dokmanovic, M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin. Investig. Drugs 14, 1497-1511 (2005).
36. Skov, S. et al. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain a and B. Cancer Res. 65, 11136-11145 (2005).
37. Johnson, C.A. & Turner, B.M. Histone deacetylases: complex transducers of nuclear signals. Semin. Cell Dev. Biol. 10, 179-188 (1999).
38. Rockman, H.A. et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 88, 8277-8281 (1991).
39. Zhou, R., Pickup, S., Glickson, J.D., Scott, C.H. & Ferrari, V.A. Assessment of global and regional myocardial function in the mouse using cine and tagged MRI. Magn. Reson. Med. 49, 760-764 (2003).
40. Matsui, T. et al. Adenoviral gene transfer of activated phosphatidylinositol 3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation 100, 2373-2379 (1999).
41. Wang, Q. et al. Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol. Cell. Biol. 19, 4008-4018 (1999).